171 related articles for article (PubMed ID: 35289201)
41. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
Ramalingam SS; Dahlberg SE; Belani CP; Saltzman JN; Pennell NA; Nambudiri GS; McCann JC; Winegarden JD; Kassem MA; Mohamed MK; Rothman JM; Lyss AP; Horn L; Stinchcombe TE; Schiller JH
J Clin Oncol; 2019 Sep; 37(26):2360-2367. PubMed ID: 31361535
[TBL] [Abstract][Full Text] [Related]
42. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
43. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
44. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
45. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
47. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Yu S; Zhang B; Xiang C; Shu Y; Wu H; Huang X; Yu Q; Yin Y; Guo R
Clin Lung Cancer; 2015 Mar; 16(2):121-7. PubMed ID: 25450874
[TBL] [Abstract][Full Text] [Related]
48. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review.
Mitsuya K; Nakasu Y; Deguchi S; Shirata K; Asakura K; Nakashima K; Endo M; Takahashi T; Hayashi N
Cancer Imaging; 2020 Nov; 20(1):84. PubMed ID: 33228799
[TBL] [Abstract][Full Text] [Related]
49. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
50. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
[TBL] [Abstract][Full Text] [Related]
51. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
53. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
55. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
56. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.
Dy GK; Molina JR; Qi Y; Ansari R; Thomas S; Ross HJ; Soori G; Anderson D; Aubry MC; Meyers J; Adjei AA; Mandrekar S; Adjei AA
J Thorac Oncol; 2014 Aug; 9(8):1146-53. PubMed ID: 25157767
[TBL] [Abstract][Full Text] [Related]
57. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
[TBL] [Abstract][Full Text] [Related]
58. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Halvorsen TO; Stokke K; Killingberg KT; Raj SX; Sørhaug S; Brustugun OT; Fløtten Ø; Helbekkmo N; Hornslien K; Madebo T; Fluge S; Grønberg BH
Acta Oncol; 2020 Sep; 59(9):1051-1057. PubMed ID: 32543258
[No Abstract] [Full Text] [Related]
60. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.
Morris PG; Reiner AS; Szenberg OR; Clarke JL; Panageas KS; Perez HR; Kris MG; Chan TA; DeAngelis LM; Omuro AM
J Thorac Oncol; 2012 Feb; 7(2):382-5. PubMed ID: 22089116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]